

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BOULAY ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/014549

FILED: 21 DECEMBER 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: BIOMARKERS FOR SENSITIVITY OF PROLIFERATIVE DISEASES
TO MTOR INHIBITORS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/014549, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909

Date: June 19, 2006

(Use several sheets if necessary)

ATTY. DOCKET NO.
33564-US-PC
APPLICATION NO.
Not Yet Known
APPLICANT
BODNAY ET AL
FILING DATE
Herewith

10/583674
APRIL 10 2006
10 JUN 2006
GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	02/46471	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
AN	2004/020582	3/11/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
AO	03/034067	4/24/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Neshat et al., "Enhanced Sensitivity of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR", Proceedings of the National Academy of Sciences of the United States of America", Vol. 98, No. 18, pp. 10314-10319 (2001).
AS	Hidalgo et al, "The Rapamycin-Sensitive Signal Transduction Pathway as a Target for Cancer Therapy", Oncogene, Vol. 19, No. 56, pp. 6680-6686 (2000) -- Abstract.
AT	Kwiatkowski et al., "A Mouse Model of TSC1 Reveals Sex-Dependent Lethality from Liver Hemangiomas, and Up-Regulation of p70S6 Kinase Activity in Tscl Null Cells", Human Molecular Genetics, Vol. 11, No. 5, pp. 525-534 (2002) -- Abstract.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33564-US-PCT
APPLICATION NO
Not Yet Known
APPLICANT
BOULAY ET AL
FILING DATE
Herewith

1A/P2006111770 19 JUN 2006
Group

EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BA	Shi et al., "Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779", Cancer Research, Vol. 62, No. 17, pp. 5027-5034 (pp. 2002).
BB	Huang et al., "Resistance to Rapamycin: A Novel Anticancer Drug", Cancer and Metastasis Reviews, Vol. 20, No. 1-2, pp. 69-78 -- Abstract.
BC	Fukazawa et al., "Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated...", Molecular Cancer Therapeutics, Vol. 1, No. 5, pp. 303-309 (2002) -- Abstract.
BD	Dumont et al., "Mechanism of Action of the Immunosuppressant Rapamycin", Life Sciences, Vol. 58, No. 5, pp. 373-395 -- Abstract.
BE	
BF	
BG	
BH	
BI	
BJ	
BK	
BL	
BM	
BN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.